ImmunityBio’s Anktiva shows success as combo treatment in NSCLC
ImmunityBio’s immunotherapy drug Anktiva (nogapendekin alfa inbakicept) has shown success in combination with a checkpoint inhibitor in two non-small cell …
Post
-
-
Akeso’s PD-1/CTLA-4 bispecific trumps chemo in frontline gastric cancer
Akeso’s cadonilimab has outperformed the activity of the current standard of care (SoC) treatment option during a real-world study in …
-
JPM26: Sanofi’s COAST 1 clinical trials exhibit positive results, with researchers optimistic for COAST 2 results for amlitelimab
Sanofi is excited for 2026. At the JP Morgan Healthcare conference, several upcoming catalyst events were highlighted, including high-profile read-outs, …
-
JPM26: 2025 a “breakout year” for rare disease biotechs
Developers in rare disease emphasise cashflow and R&D expansion as evidence of their transition from emerging biotechs to established companies …
-
JPM26: BioNTech gears up for multiproduct oncology status by 2030
BioNTech aims to have multiple commercialised cancer drugs by 2030 as the company continues its pivot away from Covid-19 vaccines. Speaking …
-
JPM26: Amgen touts MariTide’s weight loss, T2D potential off Phase II data
Amgen’s obesity and type 2 diabetes (T2D) hopeful, MariTide (maridebart cafraglutide), has demonstrated its once-quarterly dosing potential in a mid-stage …
-
Marea reports positive Phase I results for MAR002 trial in acromegaly
Marea Therapeutics has announced positive top line results from its first-in-human Phase I study of MAR002, an allosteric monoclonal antibody …
-
AbCellera begins Phase II ABCL635 trial for menopause-related VMS
AbCellera has dosed the first patient in the Phase II portion of its ongoing Phase I/II clinical trial evaluating ABCL635 …
-
JPM26: Roche’s rejuvenation strategy for the oncology and haematology portfolio
At the J.P. Morgan Healthcare Conference 2026, Roche Pharma’s CEO, Teresa Graham, shared the company’s vision for the next few …
-
Year in review: EmVenio in 2025
From a rebrand to clinical trial facilitation to the conference circuit, EmVenio covered a lot of ground. Here are some …
-
Trends for 2026: Targeted AI, continuous trials, and navigating uncertainty
As the clinical trial industry faces key challenges such as shifts, rising costs, and staffing challenges, 2026 is poised to …
-
JPM26: HIV pipeline dosing optionality gives Gilead advantage
Gilead’s range of treatments and prevention for human immunodeficiency virus (HIV), both on the market and in the pipeline, provides …
-
Vertically integrated CDMOs: The advantages and disadvantages for ADCs
Vertical integration of contract development and manufacturing organisations (CDMOs) involved in antibody-drug conjugates (ADCs) manufacturing has the potential to streamline …
-
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff
Bristol Myers Squibb (BMS) is confident pivotal readouts from its core pipeline will drive profits towards 2030 despite looming patent …
-
BMS reports positive results in Phase III SCOUT-HCM trial for oHCM
Bristol Myers Squibb (BMS) has announced positive top line results from the Phase III SCOUT-HCM trial assessing Camzyos (mavacamten) for …
